Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press119310.17650/1726-9776-2005-1-3-10-16DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫClinical application of positron emission tomography in urologic oncologyПозитронная эмиссионная томография в онкоурологической практикеGranovA. M.ГрановА. М.
Russian Federation

Saint-Petersburg

Санкт-Петербург

KarelinM. I.КарелинМ. И.
Russian Federation

Saint-Petersburg

Санкт-Петербург

RyjkovaD. V.РыжковаД. В.
Russian Federation

Saint-Petersburg

Санкт-Петербург

KostenikovN. A.КостениковН. А.
Russian Federation

Saint-Petersburg

Санкт-Петербург

ShkolnikM. I.ШкольникМ. И.
Russian Federation

Saint-Petersburg

Санкт-Петербург

TlostanovaM. S.ТлостановаМ. С.
Russian Federation

Saint-Petersburg

Санкт-Петербург

StanzhevskyA. A.СтанжевскийА. А.
Russian Federation

Saint-Petersburg

Санкт-Петербург

ProkhorovD. G.ПрохоровД. Г.
Russian Federation

Saint-Petersburg

Санкт-Петербург

Central Research Institute of Roentgenology and RadiologyЦентральный научно-исследовательский рентгенорадиологический институт МЗ СО РФ300920051310161802202018022020https://oncourology.abvpress.ru/oncur/article/view/1193

The positron emission tomography (PET) is a valuable in a clinical oncology as a highly sensitive method of diagnostics. However, PET possibilities in diagnostics of genitourinary tract tumors are less investigated. 61 patients with genitourinary lesions aged 18 to 78 years were examined. Diagnosis was verified by data of histological analysis in all cases. 18F-FDG PET (« Ecat Exact 47 « and « Ecat Exact HR + «) was performed in whole body mode. Results of our studies show high diagnostic accuracy of 18F-FDG PET at abundance definition of neoplasms and coincident with literature data. Most perspective 18F-FDG PET application is a definition of tumors follow-up efficacy. However diagnostic possibilities show poor efficacy at a hypernephroid cancer determination due to low level of a glycolysis in kind tumors.

.

1. Cremerius U., Effert P.J., Adam G. et al. FDG PET for detection and therapy control of metastatic germ cell tumour // J. Nucl. Med. — 1998;39:815—822.Cremerius U., Effert P.J., Adam G. et al. FDG PET for detection and therapy control of metastatic germ cell tumour // J. Nucl. Med. — 1998;39:815—822.2. Hoh C.K., Seltzer M.A., Franklin F.J. et al. Positron emission tomography in urologic oncology // J. Urol. — 1998;159:347—356.Hoh C.K., Seltzer M.A., Franklin F.J. et al. Positron emission tomography in urologic oncology // J. Urol. — 1998;159:347—356.3. Liu I.J., Zafar M.B., Lai Y.H. et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer // Urology. — 2001;57:108—111.Liu I.J., Zafar M.B., Lai Y.H. et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer // Urology. — 2001;57:108—111.4. Ramdave S.,Thomas G.W., Berlangieri S.U. et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma // J. Urol. — 2001;166:825— 830.Ramdave S.,Thomas G.W., Berlangieri S.U. et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma // J. Urol. — 2001;166:825— 830.5. Oyama N., Akino H., Suzuki Y. et al. The increased accumulation of 18[F]fluorodeoxyglucose in untreated prostate cancer // Jpn. J. Clin. Oncol. — 1999;29:623—629.Oyama N., Akino H., Suzuki Y. et al. The increased accumulation of 18[F]fluorodeoxyglucose in untreated prostate cancer // Jpn. J. Clin. Oncol. — 1999;29:623—629.6. Heicappell R., Muller-Mattheis V., Reinhardt M. et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose // Eur. Urol. — 1999;36:582—587.Heicappell R., Muller-Mattheis V., Reinhardt M. et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose // Eur. Urol. — 1999;36:582—587.7. Sanz G., Robles J.E., Gimenez M. et al. Positron emission tomography with 18fluorine-labeled deoxyglucose: utility in localized and advanced prostate cancer // Br. J. Urol. — 1999;84:1028—1931.Sanz G., Robles J.E., Gimenez M. et al. Positron emission tomography with 18fluorine-labeled deoxyglucose: utility in localized and advanced prostate cancer // Br. J. Urol. — 1999;84:1028—1931.8. Seltzer M.A., Barbaric Z., Belldegrun A. Comparison of helical computerized tomography, positron emission tomography, and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer // J. Urol. — 1999;162:1322—1328.Seltzer M.A., Barbaric Z., Belldegrun A. Comparison of helical computerized tomography, positron emission tomography, and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer // J. Urol. — 1999;162:1322—1328.9. Nunez R., Macapinlac H.A., Yeung H.W. et al. Combined 18F-FDG and 11C-methionine PET Scans in patients with newly progressive metastatic prostate cancer // J. Nucl. Med. — 2002;43:46—55.Nunez R., Macapinlac H.A., Yeung H.W. et al. Combined 18F-FDG and 11C-methionine PET Scans in patients with newly progressive metastatic prostate cancer // J. Nucl. Med. — 2002;43:46—55.10. Sung J., Espiritu J.I., Segall G.M. et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically advanced prostate cancer // BJU International. — 2003; 92:24—27.Sung J., Espiritu J.I., Segall G.M. et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically advanced prostate cancer // BJU International. — 2003; 92:24—27.11. Schirrmeister H., Guhlmann A., Elsner K. et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET // J. Nucl. Med. — 1999;40:1623—1629.Schirrmeister H., Guhlmann A., Elsner K. et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET // J. Nucl. Med. — 1999;40:1623—1629.12. Hoh C.K., Figlin R., Belldegrun A. Evaluation of renal cell carcinoma with whole body FDG PET // J. Nucl. Med. — 1996;37:141P.Hoh C.K., Figlin R., Belldegrun A. Evaluation of renal cell carcinoma with whole body FDG PET // J. Nucl. Med. — 1996;37:141P.13. Bachor R., Kotzerke J., Gottfried H.W. Positron emission tomography in diagnosis of renal cell carcinoma [German].— Urologe A. — 1996;35:146—150.Bachor R., Kotzerke J., Gottfried H.W. Positron emission tomography in diagnosis of renal cell carcinoma [German].— Urologe A. — 1996;35:146—150.14. Weber W.A., Avril N., Schwaiger M. Relevance of Positron Emission Tomography (PET) in Oncology // J. Strahlenther Onkol. — 1999; № 8, Vol. 175. — P.356—373Weber W.A., Avril N., Schwaiger M. Relevance of Positron Emission Tomography (PET) in Oncology // J. Strahlenther Onkol. — 1999; № 8, Vol. 175. — P.356—37315. Kocher F., Grimmel S., Hautmann R. et al. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm // J. Nucl. Med. — 1994;35(suppl):233P.Kocher F., Grimmel S., Hautmann R. et al. Preoperative lymph node staging in patients with kidney and urinary bladder neoplasm // J. Nucl. Med. — 1994;35(suppl):233P.16. Safaei A., Figlin R., Hoh C.K. et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer // Clin. Nephrol. — 2002;57:56—62.Safaei A., Figlin R., Hoh C.K. et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer // Clin. Nephrol. — 2002;57:56—62.17. Seto E., Segall G.M., Terris M.K. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan // Urology. — 2000;55:286.Seto E., Segall G.M., Terris M.K. Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scan // Urology. — 2000;55:286.18. Albers P., Bender H., Yilmaz H. et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors // Urology. — 1999;53:808—811.Albers P., Bender H., Yilmaz H. et al. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors // Urology. — 1999;53:808—811.19. Badjorin D.F., Herr H., Motzer R.J. et al. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors Semin oncol 19. —1992: P. 148—158.Badjorin D.F., Herr H., Motzer R.J. et al. Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors Semin oncol 19. —1992: P. 148—158.20. Cremerius U., Wildberger J.E., Borchers H. et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients // Urology. — 1999;54:900—904.Cremerius U., Wildberger J.E., Borchers H. et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients // Urology. — 1999;54:900—904.21. Ganjoo K.N., Chan R.J., Sharma M. et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma // J. Clin. Oncol. — 1999;17:3457—3460.Ganjoo K.N., Chan R.J., Sharma M. et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma // J. Clin. Oncol. — 1999;17:3457—3460.22. Nuutinen J., Leskinen S., Elomaa I. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. // Eur. J. Cancer. — 1997;33:1234—1241.Nuutinen J., Leskinen S., Elomaa I. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. // Eur. J. Cancer. — 1997;33:1234—1241.23. Puc H.S., Heelan R., Mazumdar M. et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial SloanKettering Cancer Center // J. Clin. Oncol. 1996;14: 454—460.Puc H.S., Heelan R., Mazumdar M. et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial SloanKettering Cancer Center // J. Clin. Oncol. 1996;14: 454—460.24. Schultz S.M., Einhorn L.H., Conces D.H. Jr. et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience // J. Clin. Oncol. — 1989;7:1497—1503.Schultz S.M., Einhorn L.H., Conces D.H. Jr. et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience // J. Clin. Oncol. — 1989;7:1497—1503.25. Shreve P.D., Grossman H.B., Gross M.D. et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[18F]fluoro-D-glucose // Radiology. — 1996. — № 199. — P. 751—756.Shreve P.D., Grossman H.B., Gross M.D. et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[18F]fluoro-D-glucose // Radiology. — 1996. — № 199. — P. 751—756.